BETHESDA, Md., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will host an investment community conference call beginning at 4:30 p.m. Eastern time on Thursday, December 9, to discuss results of the Company's Phase 3 trial with D-tagatose in Type 2 diabetes and to provide a business update.
Investors and other interested parties are invited to listen to the call by dialing (888) 563-6275 from the U.S. or (706) 634-7417 from outside the U.S. The call also will be available on the Investors section of the Company's website at www.spherix.com. Slides will accompany the conference call, and will be available in the Investors section of www.spherix.com.
A telephone replay of the conference call will be available for on-demand listening shortly after the completion of the call until 11:59 p.m. Eastern time on December 16, 2010 by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside the U.S., and entering access code 29797553. A replay also will be available at www.spherix.com.
Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is dedicated to development of D-tagatose and recently completed a Phase 3 clinical trial to study the use of D-tagatose as a treatment
|SOURCE Spherix Incorporated|
Copyright©2010 PR Newswire.
All rights reserved